CD274 and neoplasm: This superiority was supported by preclinical experiments showing that AAVS1-19bbz cells more potently eradicated Raji cells at a low infusion dose than LV-19bbz cells, and PD1-19bbz cells showed a stronger ability to eradicate tumour cells with high PD-L1 expression than LV-19bbz_PD1-KO cells, although PD1 knockout was achieved in both cell types.